Disseminated large B-cell lymphoma (DLBCL) is the most common subtype of lymphomas [61], but there is still a 40% chance of failure in current treatment; Ennishi et al. [62] found that biallelic TMEM30A loss-of-function mutation had a positive effect on the treatment of the disease in 347 patients with DLBCL. Here, CDC50A is linked to diffuse large B-cell lymphoma.